Patents by Inventor Nadine Weich

Nadine Weich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030166224
    Abstract: The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.
    Type: Application
    Filed: June 7, 2002
    Publication date: September 4, 2003
    Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporation
    Inventors: Rachel A. Meyers, Nadine Weich
  • Publication number: 20030138890
    Abstract: The invention provides isolated nucleic acids molecules, designated 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, and 84241 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 gene has been introduced or disrupted.
    Type: Application
    Filed: May 14, 2002
    Publication date: July 24, 2003
    Inventors: Maria Alexandra Glucksmann, Inmaculada Silos-Santiago, Katherine M. Galvin, Nadine Weich, Rory A. J. Curtis, Rajasekhar Bandaru, Rosana Kapeller-Libermann
  • Publication number: 20020132785
    Abstract: The invention provides isolated nucleic acids molecules, designated 13305 nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13305 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13305 gene has been introduced or disrupted. The invention still further provides isolated 13305 proteins, fusion proteins, antigenic peptides and anti-13305 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 17, 2001
    Publication date: September 19, 2002
    Inventors: Rory A.J. Curtis, Nadine Weich
  • Patent number: 6420153
    Abstract: The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: July 16, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel A. Meyers, Nadine Weich
  • Publication number: 20020037840
    Abstract: The invention provides isolated nucleic acids molecules, designated SLIC-1 nucleic acid molecules, which encode novel P-selectin glycoprotein ligand (PSGL-1) binding molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SLIC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a SLIC-1 gene has been introduced or disrupted. The invention still further provides isolated SLIC-1 proteins, fusion proteins, antigenic peptides and anti-SLIC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 23, 2001
    Publication date: March 28, 2002
    Inventors: Meike Lorenz, Ron Kriz, Nadine Weich, Gray D. Shaw
  • Publication number: 20020022249
    Abstract: The invention provides isolated nucleic acids molecules, designated 23436 nucleic acid molecules, which encode novel ubiquitin carboxy-terminal hydrolase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 23436 gene has been introduced or disrupted. The invention still further provides isolated 23436 proteins, fusion proteins, antigenic peptides and anti-23436 antibodies. Diagnostic methods utilizing compositions of the invention are also provided as are method for identifying compounds that alter a 23436 activity.
    Type: Application
    Filed: March 6, 2001
    Publication date: February 21, 2002
    Inventors: Rosana Kapeller-Libermann, Nadine Weich